Takeda's maribavir hits phase 3 goal as pharma looks forward to regulatory talks

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 4, 2020 at 11:12 AM.

  1. #1 cafead, Dec 4, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via Takeda’s experimental TAK-620 (maribavir) has hit its main phase 3 goal in helping transplant patients with refractory/resistant cytomegalovirus (CMV) infection.

    article source
     
    Quote

Reply to Thread